Physician profile
Gareth E Shemesh
NPI 1619980620
$3,624.95
in general payments reported to CMS, 2019-2025
22 companies · $273 in 2025
The $273 reported for 2025 was less than what a typical Pain Medicine (Physical Medicine & Rehabilitation) provider received nationally (typical 2025 total: $400).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,963 · 2020: $143 · 2021: $707 · 2022: $260 · 2023: $204 · 2024: $74.71 · 2025: $273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $552.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $552.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,719.05 | 2019-2021 | |
| Scilex Pharmaceuticals INC. | $366.08 | 2019-2023 | Ztlido |
| Biohaven Pharmaceuticals, INC. | $300.13 | 2021 | |
| Abbvie INC. | $177.98 | 2021-2023 | Botox, Ubrelvy, Qulipta |
| Pfizer INC. | $177.39 | 2023-2025 | |
| Collegium Pharmaceutical, INC. | $157.43 | 2019-2023 | Xtampza |
| Allergan, INC. | $120.02 | 2020-2022 | |
| Almatica Pharma LLC | $118.21 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $117.15 | 2024-2025 | Fanapt |
| Biodelivery Sciences International, INC. | $74.18 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $61.02 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $36.50 | 2025 | |
| Novartis Pharmaceuticals Corporation | $32.07 | 2019 | |
| Arbor Pharmaceuticals, INC. | $24.47 | 2020 | |
| Amgen INC. | $24.25 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $21.98 | 2024 | Ingrezza |
| Pacira Therapeutics, INC. | $19.42 | 2021 | |
| Ibsa Pharma INC. | $18.83 | 2023 | Tirosint, Licart |
| Averitas Pharma INC. | $17.63 | 2025 | Qutenza |
| Assertio Therapeutics, INC. | $14.51 | 2019 | |
| Horizon Therapeutics Plc | $13.38 | 2021 | |
| Daiichi Sankyo INC. | $13.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gareth Shemesh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.